Arvest Bank Trust Division Sells 17,283 Shares of IQVIA Holdings Inc. $IQV

Arvest Bank Trust Division decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 20.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,334 shares of the medical research company’s stock after selling 17,283 shares during the quarter. Arvest Bank Trust Division’s holdings in IQVIA were worth $14,727,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Ameliora Wealth Management Ltd. bought a new stake in shares of IQVIA in the 4th quarter worth $25,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth $27,000. Activest Wealth Management grew its stake in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares in the last quarter. Physician Wealth Advisors Inc. grew its stake in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares in the last quarter. Finally, Westside Investment Management Inc. boosted its holdings in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on IQV shares. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a report on Friday, February 6th. Jefferies Financial Group cut their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Citigroup cut their price target on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Evercore reaffirmed an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Finally, Royal Bank Of Canada started coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $225.69.

IQVIA Stock Down 3.5%

Shares of NYSE IQV opened at $161.94 on Wednesday. IQVIA Holdings Inc. has a one year low of $136.41 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm’s 50 day simple moving average is $169.78 and its two-hundred day simple moving average is $196.80. The stock has a market capitalization of $27.03 billion, a P/E ratio of 20.07, a PEG ratio of 1.61 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the business earned $2.70 earnings per share. The business’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.